RenovoRx Inc. has announced its financial results for the second quarter ended June 30, 2025. The company reported a revenue of over $400,000 from its RenovoCath device, highlighting strong demand for this FDA-cleared drug-delivery product. This marks a notable achievement for RenovoRx, as this revenue was generated without a dedicated sales and marketing team. The company also reported a net loss of $2.9 million for the quarter, an increase from the $2.4 million net loss recorded in the same period of the previous year. This $0.5 million increase in net loss was primarily attributed to a change in the fair value of the warrant liability amounting to $0.9 million, which was partially offset by a decrease in other losses. RenovoRx has also recently hired Phil Stocton as Senior Director of Sales and Market Development to build commercialization momentum and further expand its market presence. Additionally, the company announced a positive recommendation from an independent data monitoring committee to continue its pivotal Phase III TIGeR-PaC trial, based on an interim data review. As of June 30, 2025, RenovoRx had $12.3 million in cash and cash equivalents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.